Why Did Germany Reject OTC Switch Of Low-Cost Smoking Cessation Drug Cytisine?

At its first meeting of 2023, Germany's switch committee voted against switching to OTC status low-cost smoking cessation drug cytisine. Complex treatment guidelines and concerns about side effects were among the considerations leading to this decision, the recently published minutes show.